2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Profiling, Treatment Considerations, Drug Development, Drug-Drug Interactions, Supportive Care, Biological Therapies, Antibody Therapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Anticoagulant Drugs, Pharmacology, Women’s Health, Adverse Events, Biological Processes, Clinical Practice (Health Services and Quality), Clinical Guidelines, Patient Safety, Practice Models, Diseases, Bleeding and Clotting, Thromboembolism, Thrombotic Disorders, Immunology, Autoimmune Hemolytic Anemia, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Metabolic Disorders, Iron Deficiency, ALL, Aggressive Lymphoma, Research, Fundamental Science, MPN, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly, Pregnant
PAPER

1339 Overcoming inadequate aspirin response in pregnancy: Dose comparison of aspirin in pregnancies complicated by obesity

Rupsa C Boelig, MD, Natalie Selvarajah2, James V. Michael, PhD3, Steven McKenzie, MD, PhD4, Walter K Kraft, MD5
1 Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania, United States
2 Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania, United States
3 Thomas Jefferson University, Philadelphia, Pennsylvania, United States
4 Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania, United States
5 Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania, United States

Background: We previously demonstrated that among pregnant patients taking 81mg aspirin daily for preeclampsia prevention that there was a reduction in platelet inhibition with advancing gestation (3rd vs 1st and 2nd trimester), likely related to increased drug volume of distribution and/or platelet turnover as pregnancy progresses. We further found that pregnant individuals with pre-pregnancy obesity (BMI≥30) had reduced platelet inhibition with 81mg aspirin daily compared to non-obese pregnancies. 

Objective: To determine how increased aspirin dose (162mg vs 81mg daily) impacts platelet inhibition with aspirin therapy through gestation overall and among individuals with pre-pregnancy obesity (BMI≥30).

Study Design:
This is a prospective cohort study comparing individuals taking 162mg daily (N=22) with those prescribed 81mg daily (previously completed study, N=20). Aspirin was initiated <16 weeks' gestation and continued through pregnancy. Study visits were: baseline (pre-therapy), 2nd trimester (2-4 weeks after aspirin initiation), and 3rd trimester (28-32 weeks gestation). Platelet inhibition was assessed with Platelet Function Assay 100 epinephrine closure time (seconds) reported as continuous outcome and categorical with PFA-100>150seconds considered adequate aspirin response. Data presented as comparison of mean (independent sample t-test, equal variance not assumed) with mean difference (MD) and 95% confidence interval (CI) or chi-square analysis with two-sided p<0.05 considered significant. 

Results:
There were N=20 who took 81mg aspirin daily in a prior study and N=22 taking 162mg for this study. Baseline characteristics were similar between 162mg vs 81mg groups with 77% vs 80% obese 68% vs 80% Black, and 18% vs 10% Hispanic respectively. Average adherence was >90% in both cohorts across all visits. In examining platelet inhibition overall, it was similar in the 2nd trimester (163±65 vs 168±74, p=0.82), and trended to increased platelet inhibition with 162mg in 3rd trimester (171±66 vs 137±59, p=0.12, MD 34 (-9 to 76). Similarly, adequate aspirin response was similar in the 2nd trimester (57% vs 40%, p=0.27), and improved in the 3rd trimester (53% vs 18%, p=0.03). In examining the subgroup of those with pre-pregnancy obesity similarly, platelet inhibition and aspirin response were similar in the 2nd trimester (155±55 vs 151±66, p=0.88), but with a trend to greater response 56% vs 31%, p=0.15. In the 3rd trimester, platelet inhibition was improved with 162mg vs 81mg in the 3rd trimester (161±66 vs 118±28, p=0.02 MD 43 (4 to 82)) and with greater rates of adequate response (40% vs 8%, p=0.049).

Conclusion: Increased dose of aspirin (162mg daily vs 81mg daily) improves platelet inhibition with aspirin through gestation overall, and specifically in the subgroup of patients with pre-pregnancy obesity. Additional studies evaluating the pharmacokinetics of aspirin through gestation may explain these findings. Although current national guidelines recommend 81mg aspirin daily, this exploratory biomarker study suggests a mechanism by which a  higher dose of aspirin may be more effective for maintaining adequate prophylaxis through gestation overall and especially in those with pre-pregnancy obesity. 

Rupsa C Boelig, MD: COVIS Pharma - Research Funding